PNV has fallen 30% in 2021 after missing revenue expectations in January, not a good look for growth socks. The medical device business has solid access to the US & European markets and hence interesting medium term opportunities but it obviously needs to deliver. We wouldn’t be surprised to see PNV test $2 later this year hence at this stage were adopting a wait and watch approach.
MM is neutral PNV.
Add To Hit List
